Literature DB >> 17345617

Prognostic value of tumor thickness in patients with Merkel cell carcinoma.

Stephanie R Goldberg1, James P Neifeld, William J Frable.   

Abstract

BACKGROUND AND OBJECTIVES: Merkel cell carcinoma is an aggressive skin malignancy that often presents with tumor metastases. We hypothesized that tumor thickness might correlate with both regional and metastatic tumor spread and could, therefore, be used as an independent prognostic variable. The purpose of this study was to see if depth of tumor invasion would predict prognosis independent of tumor stage.
METHODS: Data pertaining to clinical presentation, pathology, treatment, and survival were collected for patients diagnosed with Merkel cell carcinoma from 1972 to 2005. Patients were staged according to AJCC guidelines. Pathologic specimens were evaluated for tumor thickness. The relationship between tumor thickness and disease-free survival or overall survival was analyzed using Kaplan-Meier survival analyses.
RESULTS: Sixty patients were identified. Five-year disease-free survivals for Stages 1, 2, and 3 patients were 20%, 33%, and 0%, respectively. Five-year overall survivals for Stages 1, 2, and 3 patients were 33.3%, 60%, and 16.7%, respectively. There was no correlation between tumor thickness and either disease-free survival or overall survival.
CONCLUSIONS: This study suggests that tumor thickness is not an independent risk factor for survival. Mean tumor thickness did increase with the AJCC stages, but this most likely represents more advanced stage of disease. Copyright 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17345617     DOI: 10.1002/jso.20737

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  7 in total

Review 1.  Merkel cell carcinoma: what do we know about it and what should we do?

Authors:  Isabel Prieto Muñoz; José Pardo Masferrer; Jesús Olivera Vegas; José Ramón Fortes Alen; Ana M Pérez Casas
Journal:  Clin Transl Oncol       Date:  2012-06       Impact factor: 3.405

2.  Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma.

Authors:  Natalie J Miller; Shailender Bhatia; Upendra Parvathaneni; Jayasri G Iyer; Paul Nghiem
Journal:  Curr Treat Options Oncol       Date:  2013-06

3.  Both tumor depth and diameter are predictive of sentinel lymph node status and survival in Merkel cell carcinoma.

Authors:  Franz O Smith; Binglin Yue; Suroosh S Marzban; Brooke L Walls; Michael Carr; Ryan S Jackson; Christopher A Puleo; Tapan Padhya; C Wayne Cruse; Ricardo J Gonzalez; Amod A Sarnaik; Michael J Schell; Ronald C DeConti; Jane L Messina; Vernon K Sondak; Jonathan S Zager
Journal:  Cancer       Date:  2015-06-02       Impact factor: 6.860

Review 4.  Merkel cell carcinoma.

Authors:  Emma Ramahi; Jehee Choi; Clifton D Fuller; Tony Y Eng
Journal:  Am J Clin Oncol       Date:  2013-06       Impact factor: 2.339

5.  A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331).

Authors:  Wolfram E Samlowski; James Moon; Ralph J Tuthill; Michael C Heinrich; Naomi S Balzer-Haas; Stuart A Merl; Ronald C DeConti; John A Thompson; Merle T Witter; Lawrence E Flaherty; Vernon K Sondak
Journal:  Am J Clin Oncol       Date:  2010-10       Impact factor: 2.339

6.  Focus Issue on Squamous Cell Carcinoma: Practical Concerns Regarding the 7th Edition AJCC Staging Guidelines.

Authors:  D Buethe; C Warner; J Miedler; C J Cockerell
Journal:  J Skin Cancer       Date:  2010-11-22

7.  Merkel cell carcinoma metastasis and dermatofibrosarcoma protuberans presenting as a collision tumour: a case report and review of the literature.

Authors:  Daniel-Johannes Tilkorn; Marcus Lehnhardt; Jörg Hauser; Adrien Daigler; Heinz Homann; Hans Steinau; Cornelius Kuhnen
Journal:  J Med Case Rep       Date:  2009-06-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.